"Adenosine Monophosphate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.
| Descriptor ID |
D000249
|
| MeSH Number(s) |
D03.633.100.759.646.138.180 D13.695.667.138.180 D13.695.827.068.180
|
| Concept/Terms |
2'-Adenylic Acid- 2'-Adenylic Acid
- 2' Adenylic Acid
- Acid, 2'-Adenylic
- 2'-Adenosine Monophosphate
- 2' Adenosine Monophosphate
- Monophosphate, 2'-Adenosine
- Adenylic Acid
- 2'-AMP
|
Below are MeSH descriptors whose meaning is more general than "Adenosine Monophosphate".
Below are MeSH descriptors whose meaning is more specific than "Adenosine Monophosphate".
This graph shows the total number of publications written about "Adenosine Monophosphate" by people in this website by year, and whether "Adenosine Monophosphate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 |
| 1998 | 1 | 0 | 1 |
| 2000 | 2 | 1 | 3 |
| 2001 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 3 | 9 | 12 |
| 2021 | 2 | 5 | 7 |
| 2022 | 0 | 3 | 3 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adenosine Monophosphate" by people in Profiles.
-
SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir. J Infect Dis. 2024 Sep 23; 230(3):624-634.
-
Remdesivir for COVID-19 in Hospitalized Children: A Phase 2/3 Study. Pediatrics. 2024 Mar 01; 153(3).
-
GABP couples oncogene signaling to telomere regulation in TERT promoter mutant cancer. Cell Rep. 2022 09 20; 40(12):111344.
-
Deconstructing the Treatment Effect of Remdesivir in the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1: Implications for Critical Care Resource Utilization. Clin Infect Dis. 2022 07 06; 74(12):2209-2217.
-
Impact of Remdesivir Incorporation along the Primer Strand on SARS-CoV-2 RNA-Dependent RNA Polymerase. J Chem Inf Model. 2022 05 23; 62(10):2456-2465.
-
Identifying the Metabolic Signatures of PPARD-Overexpressing Gastric Tumors. Int J Mol Sci. 2022 Jan 31; 23(3).
-
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial. Ann Intern Med. 2022 02; 175(2):234-243.
-
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 12; 9(12):1365-1376.
-
Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Med. 2021 11; 47(11):1258-1270.
-
Single-Cell RNA Sequencing Supports Preferential Bioactivation of Remdesivir in the Liver. Antimicrob Agents Chemother. 2021 09 17; 65(10):e0133321.